Product Description
Baminercept, an LTbetaR-Ig fusion protein, and pacteclizumab, an anti-LTalpha antibody, have been investigated as treatments for rheumatoid arthritis (RA), but they failed in both instances to produce significant clinical efficacy (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6115299/)
Mechanisms of Action: FP Inhibitor
Novel Mechanism: No
Modality: Fusion Protein
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Biogen
Company Location: CAMBRIDGE MA 02142
Company CEO: Michel Vounatsos
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Sjogren's Syndrome|Arthritis, Rheumatoid|Colitis, Ulcerative|Multiple Sclerosis, Chronic Progressive
Phase 1: Hepatitis C, Chronic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| ASJ02 | P2 |
Terminated |
Sjogren's Syndrome |
2015-01-01 |
2019-03-19 |
||
| 2010-019558-42 | P2 |
Completed |
Colitis, Ulcerative |
2012-10-23 |
2022-03-13 |
Treatments |
|
| 2007-000734-38 | P2 |
Completed |
Arthritis, Rheumatoid |
2010-02-17 |
2022-03-12 |
Treatments |
|
| 2006-005467-26 | P2 |
Terminated |
Arthritis, Rheumatoid |
2008-10-09 |
2022-03-12 |
Treatments |
|
| 2007-000733-19 | P2 |
Terminated |
Arthritis, Rheumatoid |
2008-10-09 |
2022-03-12 |
Treatments |
|
| RESPOND | P2 |
Completed |
Arthritis, Rheumatoid |
2008-10-01 |
2019-03-18 |
Treatments |
|
| RESPOND-EXT | P2 |
Terminated |
Arthritis, Rheumatoid |
2008-10-01 |
2019-03-18 |
Treatments |
|
| NCT 00458861 | P2 |
Terminated |
Arthritis, Rheumatoid |
2008-10-01 |
2019-03-21 |
Treatments |
|
| 104RA203 | P2 |
Terminated |
Arthritis, Rheumatoid |
2008-10-01 |
2019-03-21 |
Treatments |
|
| 2006-005466-39 | P2 |
Completed |
Arthritis, Rheumatoid |
2008-05-29 |
2022-03-12 |
Treatments |
|
| 104-RA-201 | P2 |
Completed |
Arthritis, Rheumatoid |
2007-05-01 |
2019-03-21 |
Treatments |
|
| BamiHepC-Study | P1 |
Unknown status |
Hepatitis C, Chronic |
None |
2019-03-19 |
Treatments |
|
| 104MS101 | P2 |
Withdrawn |
Multiple Sclerosis, Chronic Progressive |
None |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
12/01/2021 |
PubMed |
An update of targeted therapeutic options for primary Sjögren syndrome: current status and future development. |
|
06/01/2020 |
PubMed |
Sjögren's syndrome: Old and new therapeutic targets. |